CREBBP lysine acetyltransferase domain mutations create zombie enzymes that alter chromatin loading dynamics and prevent EP300 redundancy

Epigenetic regulation of gene expression is fundamental to cell state transitions. A prominent example of this is the epigenetically-regulated generation of transitory cells states within the germinal center (GC) reaction that are required for humoral immunity. The deregulation of these processes through somatic mutations can give rise to B-cell lymphoma, thus studying these mutations can provide insight into fundamental mechanisms underlying epigenetic regulation of gene expression as well as GC B-cell and lymphoma biology. Here we show that classes of mutations in the CREBBP lysine acetyltransferase gene result in different structure, catalytic activity and function. We discover that CREBBP and its paralog EP300 are dynamically and reciprocally loaded onto chromatin during a signal-responsive cell state transitions within the GC. Mutation of CREBBP in GC-derived lymphoma interrupt signal-responsive CREBBP loading onto chromatin, while also inhibiting EP300 redundancy. These observations lead to a model in which CREBBP or EP300 loss of function through acetyltransferase domain mutations, which occur frequently in both hematopoietic and solid tumors, create a zombie enzyme that retards the function of the active paralog by binding limiting concentrations of transcription factor substrate and preventing signal-responsive enhancer activation.

[1]  A. Feinberg,et al.  Epigenetics as a mediator of plasticity in cancer , 2023, Science.

[2]  G. Slack,et al.  BCL10 Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL , 2022, Cancer discovery.

[3]  Yihan Lin,et al.  Co-condensation between transcription factor and coactivator p300 modulates transcriptional bursting kinetics. , 2021, Molecular cell.

[4]  C. Chomienne,et al.  Human CREBBP acetyltransferase is impaired by etoposide quinone, an oxidative and leukemogenic metabolite of the anticancer drug etoposide through modification of redox-sensitive zinc-finger cysteine residues. , 2020, Free radical biology & medicine.

[5]  Jorja G. Henikoff,et al.  Efficient chromatin accessibility mapping in situ by nucleosome-tethered tagmentation , 2020, eLife.

[6]  S. Barrans,et al.  Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report. , 2020, Blood.

[7]  Steven J. M. Jones,et al.  Pan-cancer analysis of whole genomes , 2020, Nature.

[8]  D. Gerlich,et al.  Organization of Chromatin by Intrinsic and Regulated Phase Separation , 2019, Cell.

[9]  K. Basso,et al.  Unique and Shared Epigenetic Programs of the CREBBP and EP300 Acetyltransferases in Germinal Center B Cells Reveal Targetable Dependencies in Lymphoma. , 2019, Immunity.

[10]  Steven Henikoff,et al.  Improved CUT&RUN chromatin profiling tools , 2019, eLife.

[11]  Michael R. Green,et al.  Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma , 2019, bioRxiv.

[12]  Michael R. Green,et al.  Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma , 2019, bioRxiv.

[13]  Stefano Monti,et al.  Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes , 2018, Nature Medicine.

[14]  Roland Schmitz,et al.  Genetics and Pathogenesis of Diffuse Large B‐Cell Lymphoma , 2018, The New England journal of medicine.

[15]  Michael R. Green,et al.  Chromatin modifying gene mutations in follicular lymphoma. , 2018, Blood.

[16]  D. Dunson,et al.  Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma , 2017, Cell.

[17]  S. Henikoff,et al.  Targeted in situ genome-wide profiling with high efficiency for low cell numbers , 2018, Nature Protocols.

[18]  Nicholas A. Sinnott-Armstrong,et al.  An improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues , 2017, Nature Methods.

[19]  H. Dyson,et al.  Role of the CBP catalytic core in intramolecular SUMOylation and control of histone H3 acetylation , 2017, Proceedings of the National Academy of Sciences.

[20]  P. Eyers,et al.  Bio-Zombie: the rise of pseudoenzymes in biology. , 2017, Biochemical Society transactions.

[21]  Christopher A. Miller,et al.  Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma. , 2017, Blood.

[22]  Steven Henikoff,et al.  An efficient targeted nuclease strategy for high-resolution mapping of DNA binding sites , 2016, bioRxiv.

[23]  L. Staudt,et al.  Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets , 2016, Leukemia.

[24]  Ali Bashashati,et al.  Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study , 2016, PLoS medicine.

[25]  P. Eyers,et al.  The evolving world of pseudoenzymes: proteins, prejudice and zombies , 2016, BMC Biology.

[26]  A. Rosenwald,et al.  Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. , 2016, Blood.

[27]  Karen E Gascoigne,et al.  Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma , 2016, eLife.

[28]  L. Fritsch,et al.  An acetyltransferase assay for CREB-binding protein based on reverse phase-ultra-fast liquid chromatography of fluorescent histone H3 peptides. , 2015, Analytical biochemistry.

[29]  M. Lunning,et al.  Mutation of chromatin modifiers; an emerging hallmark of germinal center B-cell lymphomas , 2015, Blood Cancer Journal.

[30]  Ash A. Alizadeh,et al.  Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation , 2015, Proceedings of the National Academy of Sciences.

[31]  U. Klein,et al.  Dynamics of B cells in germinal centres , 2015, Nature Reviews Immunology.

[32]  O. Griffith,et al.  COSMIC (Catalogue of Somatic Mutations in Cancer) , 2014 .

[33]  L. Staudt,et al.  Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma. , 2014, Blood.

[34]  A. Andrews,et al.  Differences in Specificity and Selectivity Between CBP and p300 Acetylation of Histone H3 and H3/H4 , 2013, Biochemistry.

[35]  David A. Orlando,et al.  Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes , 2013, Cell.

[36]  Kenneth H. Buetow,et al.  CREBBP mutations in relapsed acute lymphoblastic leukaemia , 2011, Nature.

[37]  Raul Rabadan,et al.  Inactivating mutations of acetyltransferase genes in B-cell lymphoma , 2010, Nature.

[38]  M. Esteller,et al.  Aberrant epigenetic landscape in cancer: how cellular identity goes awry. , 2010, Developmental cell.

[39]  Ling Wang,et al.  The structural basis of protein acetylation by the p300/CBP transcriptional coactivator , 2008, Nature.

[40]  R. Roeder,et al.  Regulation of the p300 HAT domain via a novel activation loop , 2004, Nature Structural &Molecular Biology.

[41]  Shicai Wang,et al.  COSMIC: the Catalogue Of Somatic Mutations In Cancer , 2018, Nucleic Acids Res..

[42]  Yingming Zhao,et al.  Structure of p300 in complex with acyl-CoA variants. , 2017, Nature chemical biology.

[43]  M. Hung,et al.  Phosphorylation of CBP by IKKalpha promotes cell growth by switching the binding preference of CBP from p53 to NF-kappaB. , 2007, Molecular cell.